CA1060797A - Isolation of original protein endotoxin from pseudomonas aeruginosa - Google Patents
Isolation of original protein endotoxin from pseudomonas aeruginosaInfo
- Publication number
- CA1060797A CA1060797A CA246,619A CA246619A CA1060797A CA 1060797 A CA1060797 A CA 1060797A CA 246619 A CA246619 A CA 246619A CA 1060797 A CA1060797 A CA 1060797A
- Authority
- CA
- Canada
- Prior art keywords
- component
- pseudomonas aeruginosa
- bacterial
- oep
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/874—Pseudomonas
- Y10S435/875—Pseudomonas aeruginosa
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP50055979A JPS51133489A (en) | 1975-05-14 | 1975-05-14 | Process for producing microbial components of pseudomonas aeruginosa h aving antimicrobial and antitumor activities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1060797A true CA1060797A (en) | 1979-08-21 |
Family
ID=13014183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA246,619A Expired CA1060797A (en) | 1975-05-14 | 1976-02-26 | Isolation of original protein endotoxin from pseudomonas aeruginosa |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4079126A (enExample) |
| JP (1) | JPS51133489A (enExample) |
| CA (1) | CA1060797A (enExample) |
| DE (1) | DE2610504C2 (enExample) |
| FR (1) | FR2311093A1 (enExample) |
| GB (1) | GB1537509A (enExample) |
| SE (1) | SE434701B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1085293A (en) * | 1976-02-05 | 1980-09-09 | Yuzuru Homma | Toxoids derived from protease and elastase of pseudomonas aeruginosa and production thereof |
| JPS5296729A (en) * | 1976-02-05 | 1977-08-13 | Shionogi & Co Ltd | Mixed vaccin for cyanomycosis |
| US4479935A (en) * | 1980-04-22 | 1984-10-30 | Institut Pasteur | Fractions extracted from aerobic bacteria, endowed with antitumoral, antibacterial and interferon inducing properties, and process for their preparation |
| CA1256370A (en) * | 1984-02-24 | 1989-06-27 | Yuzuru Homma | Toxoids of elastase of pseudomonas aeruginosa origin |
| AT384032B (de) * | 1985-01-14 | 1987-09-25 | Immuno Ag | Verfahren zur herstellung von polydispersen nativen pseudomonas-flagella(h)-antigenen (fag) |
| US5179001A (en) * | 1985-09-27 | 1993-01-12 | The Regents Of The University Of California | Detection and monitoring of chronic and gram-negative infection |
| AT391080B (de) * | 1986-06-24 | 1990-08-10 | Immuno Ag | Verfahren zur herstellung von gegen pseudomonas aeruginosa infektionen wirksamen praeparationen |
| US5237053A (en) * | 1986-06-24 | 1993-08-17 | Immuno Aktiengesellschaft | Preparation active against Pseudomonas aeruginosa infections and methods of producing them |
| FR2613380B1 (fr) * | 1987-04-06 | 1989-11-17 | Pasteur Institut | Nouvelle substance adjuvante de certains antimitotiques chimiques, procede d'obtention de cette substance a partir de cultures de vibrio cholerae, agents therapeutiques contenant ladite substance |
| DE69032484D1 (de) * | 1989-10-27 | 1998-08-20 | Arch Dev Corp | Zusammensetzungen und deren verwendung zur förderung der immunopotentiation |
| US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
| US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
| US20030108548A1 (en) * | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US8663634B2 (en) * | 2005-07-11 | 2014-03-04 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| JP2009544761A (ja) * | 2006-06-14 | 2009-12-17 | マクロジェニクス,インコーポレーテッド | 低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法 |
| CA2673470A1 (en) * | 2006-12-21 | 2008-07-03 | Macrogenics, Inc. | Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity |
| KR102198749B1 (ko) * | 2011-03-02 | 2021-01-06 | 제롬 쉔타그 | 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단 |
| CN109401992B (zh) * | 2017-08-18 | 2021-07-23 | 黑龙江省科学院微生物研究所 | 一株高产内毒素蛋白的铜绿假单胞菌及其应用 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS496096B1 (enExample) * | 1970-09-30 | 1974-02-12 | ||
| GB1365950A (en) * | 1970-10-20 | 1974-09-04 | Eisai Co Ltd | Pharmaceutical composition comprising a cell wall protein compo nent of pseudomonas aeruginosa |
| FR2184531B1 (enExample) * | 1972-05-19 | 1975-10-17 | Anvar |
-
1975
- 1975-05-14 JP JP50055979A patent/JPS51133489A/ja active Granted
-
1976
- 1976-02-16 GB GB5938/76A patent/GB1537509A/en not_active Expired
- 1976-02-18 SE SE7601841A patent/SE434701B/xx unknown
- 1976-02-26 CA CA246,619A patent/CA1060797A/en not_active Expired
- 1976-03-01 FR FR7605759A patent/FR2311093A1/fr active Granted
- 1976-03-12 DE DE2610504A patent/DE2610504C2/de not_active Expired
- 1976-03-19 US US05/668,564 patent/US4079126A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| SE434701B (sv) | 1984-08-13 |
| DE2610504A1 (de) | 1976-11-25 |
| DE2610504C2 (de) | 1985-07-11 |
| GB1537509A (en) | 1978-12-29 |
| FR2311093A1 (fr) | 1976-12-10 |
| SE7601841L (sv) | 1976-11-15 |
| JPS51133489A (en) | 1976-11-19 |
| JPS6123167B2 (enExample) | 1986-06-04 |
| FR2311093B1 (enExample) | 1979-06-29 |
| US4079126A (en) | 1978-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6977076B2 (en) | Methods for obtaining from Chlorella extract polysaccharides having immunomodulating properties | |
| US4079126A (en) | Method of preparing a component consisting of sugar, lipid and protein derived from Pseudomonas aeruginosa which possess anti-tumor and interferon inducing properties | |
| Beachey et al. | Purification and properties of M protein extracted from group A streptococci with pepsin: covalent structure of the amino terminal region of type 24 M antigen | |
| Cunningham et al. | Further purification of group A streptococcal pyrogenic exotoxin and characterization of the purified toxin | |
| Waśniowska et al. | The amino acids of M and N blood group glycopeptides are different | |
| Ellouz et al. | Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives | |
| Restrepo-Moreno et al. | Nature of the skin-reactive principle in culture filtrates prepared from Paracoccidioides brasiliensis | |
| AU2001287382A1 (en) | Chlorella preparations exhibiting immunomodulating properties | |
| HU181957B (en) | Process for producing protein-type antygene compositions /preparates/ against caries | |
| CA1037028A (en) | Watersoluble extracts of corynebacteria, process for obtaining them and their use | |
| Joseph et al. | Peptidoglycan of free-living anaerobic spirochetes | |
| Iacono et al. | Isolation and immunochemical characterization of the group-specific antigen of Streptococcus mutants 6715 | |
| Kamiyama et al. | Studies on the structure of α1-acid glycoprotein II. Preparation and characterization of a glycopeptide fraction | |
| US4152423A (en) | Immunological agents | |
| US4734403A (en) | Membrane polysaccharides which are useful as immunostimulants | |
| KR930002736B1 (ko) | 에피더민의 제조방법 | |
| Okuda et al. | An envelope-specific glycoprotein from Escherichia coli B | |
| GB2182937A (en) | Common antigen (psc-a)to pseudomonas aeruginosa | |
| Lopez-Merino et al. | Immunization by an insoluble fraction extracted from Brucella melitensis: immunological and chemical characterization of the active substances | |
| CA1043776A (en) | Acetylated watersoluble extracts of corynebacteria, process for obtaining them and their use | |
| Lankford et al. | Virulence factors of choleragenic vibrios | |
| US4001395A (en) | Hydrosoluble extracts of mycobacteria | |
| KR0141678B1 (ko) | 정제 진드기 알레르겐 | |
| Kirkpatrick et al. | Transfer factor | |
| Watanabe et al. | Inhibiting Materials for γ Phage Adsorption to the Cell Wall of Bacillus anthracis, Strain Pasteur No. 2‐H |